Universe Pharmaceuticals Reports Decline in Financial Performance Amid Regulatory Changes

Universe Pharmaceuticals reported a 29% decline in revenues to $9.2 million for the six months ended March 31, 2025, primarily due to a drop in third-party product sales and a rise in operational losses. Net losses increased by 37.4%, and general and administrative expenses rose due to consulting fees. The company faces challenges in adapting to regulatory changes and market dynamics, impacting its profitability and market positioning.